These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 26019627)
1. Combination of Ma R; Xu Y; Jiang W; Zhang W Biotechnol Biotechnol Equip; 2015 Jan; 29(1):139-146. PubMed ID: 26019627 [TBL] [Abstract][Full Text] [Related]
2. [The effects and mechanism of Tripterygium wilfordii Hook F combination with irbesartan on urinary podocyte excretion in diabetic nephropathy patients]. Ma RX; Zhao N; Zhang W Zhonghua Nei Ke Za Zhi; 2013 Jun; 52(6):469-73. PubMed ID: 24059992 [TBL] [Abstract][Full Text] [Related]
3. Low-dose of multi-glycoside of Tripterygium wilfordii Hook. f., a natural regulator of TGF-β1/Smad signaling activity improves adriamycin-induced glomerulosclerosis in vivo. Wan YG; Che XY; Sun W; Huang YR; Meng XJ; Chen HL; Shi XM; Tu Y; Wu W; Liu YL J Ethnopharmacol; 2014 Feb; 151(3):1079-1089. PubMed ID: 24362077 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of Tripterygium wilfordii Hook F on animal model of Diabetic Kidney Diseases: A systematic review and meta-analysis. Jin D; Yu M; Li X; Wang X J Ethnopharmacol; 2021 Dec; 281():114536. PubMed ID: 34419607 [TBL] [Abstract][Full Text] [Related]
5. [Triptolide combined with irbesartan synergistically blocks podocyte injury in a type 2 diabetes rat model]. Ma RX; Xu Y; Zhang J; Li YS; Liu LQ Zhonghua Nei Ke Za Zhi; 2012 Feb; 51(2):117-22. PubMed ID: 22490812 [TBL] [Abstract][Full Text] [Related]
6. The effects of Cheng Y; Liu Y; Lin L; Li D; Peng L; Zheng K; Tao J; Li M Ren Fail; 2024 Dec; 46(1):2295425. PubMed ID: 38178377 [TBL] [Abstract][Full Text] [Related]
7. A Network Pharmacology-Based Strategy for Unveiling the Mechanisms of Tripterygium Wilfordii Hook F against Diabetic Kidney Disease. Wang Y; Liu T; Ma F; Lu X; Mao H; Zhou W; Yang L; Li P; Zhan Y J Diabetes Res; 2020; 2020():2421631. PubMed ID: 33274236 [TBL] [Abstract][Full Text] [Related]
8. Promotion of chemerin in rat diabetic kidney disease through enhancement of TGF-β1/Smads/CTGF pathway. Wang W; Guo J; Wang D Am J Transl Res; 2021; 13(9):10206-10217. PubMed ID: 34650691 [TBL] [Abstract][Full Text] [Related]
9. Tripterygium glycoside protects diabetic kidney disease mouse serum-induced podocyte injury by upregulating autophagy and downregulating β-arrestin-1. Zhan H; Jin J; Liang S; Zhao L; Gong J; He Q Histol Histopathol; 2019 Aug; 34(8):943-952. PubMed ID: 30839094 [TBL] [Abstract][Full Text] [Related]
10. Tripterygium glycoside suppresses epithelial‑to‑mesenchymal transition of diabetic kidney disease podocytes by targeting autophagy through the mTOR/Twist1 pathway. Tao M; Zheng D; Liang X; Wu D; Hu K; Jin J; He Q Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34165172 [TBL] [Abstract][Full Text] [Related]
11. The Active Compounds and Therapeutic Target of Liu P; Zhang J; Wang Y; Shen Z; Wang C; Chen DQ; Qiu X Front Med (Lausanne); 2021; 8():747922. PubMed ID: 34621768 [No Abstract] [Full Text] [Related]
12. [Effect of multi-glycoside of Tripterygium wilfordii Hook. f. in intervening TGF-beta1/Smad signaling pathway of adriamycin-induced nephropathy model rat]. Wan YG; Sun W; Dou CH Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 Apr; 31(4):517-24. PubMed ID: 21608226 [TBL] [Abstract][Full Text] [Related]
13. Protective Effect of Irbesartan by Inhibiting ANGPTL2 Expression in Diabetic Kidney Disease. Fang LN; Zhong S; Huang LJ; Lu B; Shen LW; Tang FY; Sun HP; Zhang L Curr Med Sci; 2020 Dec; 40(6):1114-1120. PubMed ID: 33263178 [TBL] [Abstract][Full Text] [Related]
14. [Transforming growth factor-β1 regulates renal α3 and β1 integrin expressions in diabetic rats: a new insight into the renoprotective effect of irbesartan]. Zhu Y; Shen J; Hu YY; Tang JL; Liu S Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(6):1059-62. PubMed ID: 21690069 [TBL] [Abstract][Full Text] [Related]
15. Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats. Liu BC; Chen Q; Luo DD; Sun J; Phillips AO; Ruan XZ; Liu NF Acta Pharmacol Sin; 2003 Jan; 24(1):67-73. PubMed ID: 12511232 [TBL] [Abstract][Full Text] [Related]
16. MicroRNA-26a inhibits TGF-β-induced extracellular matrix protein expression in podocytes by targeting CTGF and is downregulated in diabetic nephropathy. Koga K; Yokoi H; Mori K; Kasahara M; Kuwabara T; Imamaki H; Ishii A; Mori KP; Kato Y; Ohno S; Toda N; Saleem MA; Sugawara A; Nakao K; Yanagita M; Mukoyama M Diabetologia; 2015 Sep; 58(9):2169-80. PubMed ID: 26063197 [TBL] [Abstract][Full Text] [Related]
17. STIM promotes the epithelial-mesenchymal transition of podocytes through regulation of FcγRII activity in diabetic nephropathy. Jin J; Ye M; Hu K; Gong J; He Q Histol Histopathol; 2019 Jun; 34(6):671-682. PubMed ID: 30475382 [TBL] [Abstract][Full Text] [Related]
18. Mechanism for the therapeutic effect of Zhao J; Liu H Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 May; 47(5):573-582. PubMed ID: 35753727 [TBL] [Abstract][Full Text] [Related]
19. [Triptolide inhibits NLRP3 inflammasome activation and ameliorates podocyte epithelial-mesenchymal transition induced by high glucose]. Wu W; Liu BH; Wan YG; Sun W; Liu YL; Wang WW; Fang QJ; Tu Y; Yee HY; Yuan CC; Wan ZY Zhongguo Zhong Yao Za Zhi; 2019 Dec; 44(24):5457-5464. PubMed ID: 32237395 [TBL] [Abstract][Full Text] [Related]
20. Protection of CTGF Antibody Against Diabetic Nephropathy in Mice Via Reducing Glomerular β-Catenin Expression and Podocyte Epithelial-Mesenchymal Transition. Dai HY; Ma LN; Cao Y; Chen XL; Shi H; Fan YP; Yang B J Cell Biochem; 2017 Nov; 118(11):3706-3712. PubMed ID: 28370212 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]